Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Hoffmann-La Roche
National Cancer Institute (NCI)
Hoffmann-La Roche
Bristol-Myers Squibb
National Cancer Institute (NCI)
Celltrion
National Cancer Institute (NCI)
Samsung Bioepis Co., Ltd.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Pfizer
Taiho Oncology, Inc.
Ono Pharmaceutical Co. Ltd
Biocad
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc.
Takeda
Hoffmann-La Roche
National Cancer Institute (NCI)
Henry Ford Health System
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
SWOG Cancer Research Network
National Cancer Institute, Naples
Spanish Breast Cancer Research Group
Hoffmann-La Roche
Hoffmann-La Roche
National Cancer Institute (NCI)
Hoffmann-La Roche
Viatris Inc.
Centus Biotherapeutics Limited
Eli Lilly and Company
Hoffmann-La Roche
National Cancer Institute (NCI)
mAbxience Research S.L.
AryoGen Pharmed Co.